A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL).

Trial Profile

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs JCAR 017 (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms TRANSCEND; TRANSCEND NHL 001
  • Sponsors Juno Therapeutics
  • Most Recent Events

    • 06 Jun 2017 Results (n=28) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 According to a Juno Therapeutics media release, The core analysis (N=44) includes patients that represent the population that will move forward into the upcoming pivotal trial (CTP700272663)
    • 06 Jun 2017 According to a Juno Therapeutics media release, Jeremy Abramson M.D., of Massachusetts General Hospital Cancer Center is the principal investigator of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top